Grieger E, Schneider H, Weichler U, Peter J H, von Wichert P, Voigt K
Medizinische Poliklinik, Universität Marburg.
Pneumologie. 1993 Mar;47 Suppl 1:166-9.
We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60%, over the total period at least 25%). No patient had a responder type II profile. 13 patients were nonresponders (improvement in initial AI and over the whole period not more than 25%, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophyllin leading to discontinuation of the treatment course occurred in 5 patients. 22 patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. Hence, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.
我们进行了一项前瞻性研究，对一组（截至目前）65名睡眠呼吸暂停患者在茶碱治疗（500毫克/天）期间根据反应类型进行分类并随访。将呼吸暂停指数（AI）的变化和临床症状作为反应标准。在3个月的随访期内观察到AI显著降低。在6个月后的最后一次对照测量中，目前尚未检测到显著变化。10名患者被归类为I型反应者（初始AI改善60%，在整个期间至少改善25%）。没有患者具有II型反应者特征。13名患者为无反应者（初始AI改善且在整个期间不超过25%，临床症状模式无改善）。13名患者因不依从退出试验。5名患者出现了导致治疗过程中断的典型茶碱副作用。在撰写本文时，22名患者尚未完成疗程。对患者的标准化询问显示，情绪状态有明显改善，尤其是在白天入睡倾向和早晨的清爽感方面。夜间不适仅在少数孤立病例中出现。因此，每晚服用500毫克/天的缓释茶碱制剂仍然是治疗睡眠呼吸暂停的一种有意义的治疗方法。
